Genenta Science S.p.A. (GNTA) Research

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

Market snapshot

Symbol
GNTA
Price
$1.68
Day change
-8.70%
Market cap
$28.1M
P/E ratio
-4.97x
52-week range
0.55-10
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Barinthus Biotherapeutics plc (BRNS)
  • CEL-SCI Corporation (CVM)
  • INmune Bio, Inc. (INMB)
  • Century Therapeutics, Inc. (IPSC)
  • Jupiter Neurosciences, Inc. (JUNS)
  • Medicus Pharma Ltd. Common Stock (MDCX)
  • Mersana Therapeutics, Inc. (MRSN)
  • Serina Therapeutics, Inc. (SER)

Recent insider activity

  • Paracchi Pierluigi — A-Award (100000 shares) on 2026-03-30
  • Galimi Francesco — A-Award (20000 shares) on 2026-03-30
  • PARACCHI GIACOMOANTONIO — A-Award (20000 shares) on 2026-03-30
  • Sharei Armon — A-Award (20000 shares) on 2026-03-30
  • Mutti Miguel Maria — A-Award (20000 shares) on 2026-03-30

Open Genenta Science S.p.A. (GNTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.